GCDH
Glutaryl-CoA dehydrogenase, mitochondrial
Also known as: ACAD5, GCD, GCDH_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q92947
- Gene
- GCDH
- Ensembl
- ENSG00000105607
- Chromosome
- 19
- Canonical length
- 438 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Mitochondria
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
The protein encoded by this gene belongs to the acyl-CoA dehydrogenase family. It catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA and CO(2) in the degradative pathway of L-lysine, L-hydroxylysine, and L-tryptophan metabolism. It uses electron transfer flavoprotein as its electron acceptor. The enzyme exists in the mitochondrial matrix as a homotetramer of 45-kD subunits. Mutations in this gene result in the metabolic disorder glutaric aciduria type 1, which is also known as glutaric acidemia type I. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome 12. [provided by RefSeq, Mar 2013]
Canonical amino-acid sequenceUniProt
438 residues, UniProt reviewed canonical sequence.
>Q92947|GCDH
1 MALRGVSVRL LSRGPGLHVL RTWVSSAAQT EKGGRTQSQL AKSSRPEFDW QDPLVLEEQL
61 TTDEILIRDT FRTYCQERLM PRILLANRNE VFHREIISEM GELGVLGPTI KGYGCAGVSS
121 VAYGLLAREL ERVDSGYRSA MSVQSSLVMH PIYAYGSEEQ RQKYLPQLAK GELLGCFGLT
181 EPNSGSDPSS METRAHYNSS NKSYTLNGTK TWITNSPMAD LFVVWARCED GCIRGFLLEK
241 GMRGLSAPRI QGKFSLRASA TGMIIMDGVE VPEENVLPGA SSLGGPFGCL NNARYGIAWG
301 VLGASEFCLH TARQYALDRM QFGVPLARNQ LIQKKLADML TEITLGLHAC LQLGRLKDQD
361 KAAPEMVSLL KRNNCGKALD IARQARDMLG GNGISDEYHV IRHAMNLEAV NTYEGTHDIH
421 ALILGRAITG IQAFTASKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GCDH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 87 nTPM
Expression across tissuesHPA
Tissue
- liver: 87 nTPM
- choroid plexus: 30 nTPM
- skeletal muscle: 28 nTPM
- heart muscle: 28 nTPM
- tongue: 25 nTPM
- kidney: 23 nTPM
Single-cell type
- hepatocytes: 154 nCPM
- breast lactating cells: 74 nCPM
- bergmann glia: 53 nCPM
- esophageal basal cells: 39 nCPM
- ovarian stromal cells: 37 nCPM
- parietal cells: 35 nCPM
Immune cell
- NK-cell: 39 nTPM
- naive CD4 T-cell: 31 nTPM
- myeloid DC: 24 nTPM
- naive CD8 T-cell: 24 nTPM
- memory CD4 T-cell: 23 nTPM
- T-reg: 21 nTPM
Brain region
- white matter: 25 nTPM
- basal ganglia: 25 nTPM
- cerebellum: 24 nTPM
- choroid plexus: 24 nTPM
- medulla oblongata: 22 nTPM
- cerebral cortex: 22 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GCDH.
Disease | AllUniProt
Conditions GCDH is implicated in, by any mechanism.
- Glutaric aciduria 1 (GA1) MIM:231670
Disease | GeneticClinVar
328 pathogenic / likely-pathogenic of 1,035 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Glutaric aciduria, type 1
- GCDH-related disorder
- Inborn genetic diseases
- Glutaric acidaemia I newborn screening follow up
- Colon adenocarcinoma
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.64
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.31
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- fatty acid beta-oxidation using acyl-CoA dehydrogenase
- fatty-acyl-CoA biosynthetic process
- L-tryptophan metabolic process
Molecular functions
- fatty-acyl-CoA binding
- flavin adenine dinucleotide binding
- glutaryl-CoA dehydrogenase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Acyl-CoA dehydrogenase, conserved site
- Acyl-CoA dehydrogenase/oxidase, middle domain
- Acyl-CoA dehydrogenase/oxidase, C-terminal
- Acyl-CoA dehydrogenase/oxidase, N-terminal and middle domain superfamily
- Acyl-CoA dehydrogenase/oxidase, N-terminal
- Acyl-CoA dehydrogenase-like, C-terminal
- Acyl-CoA dehydrogenase/oxidase, N-terminal domain superfamily
- Acyl-CoA oxidase/dehydrogenase, middle domain superfamily
- Acyl-CoA dehydrogenase, C-terminal domain
- Acyl-CoA dehydrogenase, middle domain
- Acyl-CoA dehydrogenase, N-terminal domain
- Glutaryl-CoA dehydrogenase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of GCDH in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GCDH as an antibody target. Whether an autoantibody or antibody against GCDH could matter depends on whether native GCDH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GCDH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GCDH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...